TriangleEmavusertib + Chemoimmunotherapy (NCT07107750)
Emavusertib + Chemoimmunotherapy trial for Untreated Advanced Biliary Tract Cancer (NCT07107750). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced biliary tract cancer, including bile duct and gallbladder cancer, who have not been treated yet.
The idea: add emavusertib, a pill that blocks a protein called IRAK4, to the standard first treatment of gemcitabine and cisplatin chemotherapy plus durvalumab immunotherapy. Lab work suggests blocking IRAK4 may weaken the tumor's survival signals and its protective surroundings, so chemotherapy and immunotherapy work better.
The study looks at safety and the dose to use going forward.
This phase 1 study plans 48 patients. At Washington University School of Medicine in St. Louis, Olivia Aranha leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.